Orthobiologics Market Size, Share & Analysis Report, 2022-2030
According to Nova one advisor, the global Orthobiologics market was valued at USD 5.11 billion in 2021 and it is expected to hit around USD 7.18 billion by 2030 with a CAGR of 4.10% during the forecast period 2022 to 2030.
Orthobiologics encompass a broad range of technologies with a biological or biochemical component. Examples include biologic factors delivered through a device, bone graft materials, cell therapies, and resorbable scaffolds to reinforce soft tissue. Rise in usage of orthobiologics products and orthopedic devices, and the integration of biology and biochemistry in the treatment of bone and soft tissue injuries are driving the orthobiologics market. Orthobiologics are medications that speed up the body's natural healing process. They can help repair osteoarthritis damage as well as accelerate the recovery of strained muscles, tendons, and ligaments. Orthobiologics are made with components that are naturally found in the human body. Rise in prevalence of inflammatory conditions such as osteoarthritis and tendinitis along with increase in participation in a sports activity that can lead to ligament or muscle injury in teenagers and young adults is expected to drive the global orthobiologics market during the forecast period. Orthobiologics, which has the potential to accelerate the healing process for pain and injuries, provides solutions and hope for people who want to live a pain-free life.
Report Scope of the Orthobiologics Market
|
Report Coverage |
Details |
|
Market Size |
USD 7.18 Billion by 2030 |
|
Growth Rate |
CAGR of 4.10% from 2022 to 2030 |
|
Largest Market |
North America |
|
Fastest Growing Market |
Asia Pacific |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2030 |
|
Segments Covered |
Product, Application, End-user and Region, |
|
Companies Mentioned |
|
Surge in Sports Injuries to Drive Global Orthobiologics Market
Sports injuries have become a major concern for athletes. The musculoskeletal system, which consists of the muscles, tendons, ligaments, fascia, nerves, bones, and tissues, is involved in sports injuries. Falls, excessive exertion, and fractures are the primary causes of these injuries. Lower and upper extremities suffer the majority of sports-related injuries and muscle injuries. Orthobiologics, such as stem cells, are used to treat common, acute, and chronic sports injuries. Year-round participation in a single sport is the most significant cause of increase in youth injuries. Rugby, combat sports, field hockey, basketball, and handball account for the most number of hand injuries.
In the last few decades, there has been an increase in sports participation by children and adolescents at an early age in the U.S. There has also been a rise in specialization in sports at a very early age. This trend has contributed to the patterns of injuries seen in young athletes. Injuries previously observed in mature athletes are now being reported in young athletes. According to a study published by the National Library of Medicine, 3.5 million youth under the age of 15 receive medical care each year in the U.S. for injuries sustained during sports practice.
Increase in Demand for Non-surgical Treatments for Osteoarthritis to Propel Viscosupplements Segment
In terms of product, the viscosupplements segment held significant market share in 2021. Increase in demand for non-surgical treatments for osteoarthritis, rise in prevalence of lifestyle-induced disorders, and advancements in hyaluronic acid-based therapies are expected to drive the viscosupplements segment during the forecast period. Viscosupplements demonstrate clinical efficacy and is the most effective treatment for knee osteoarthritis. Osteoarthritis is the most common joint disorder in the U.S., affecting nearly 27 million people. Osteoarthritis of the knee alone affects 10% of men and 13% of women over the age of 60. Viscosupplementation can significantly reduce pain while improving joint mobility and function, making daily activities and even athletic or strenuous exercise less painful. Manufacturers of viscosupplementation devices are striving to develop and get approval for new medicines to treat osteoarthritis of the elbow, hip, and knee.
Rise in Number of Spinal and Sports-related Injuries to Boost Demand for Spinal Fusion Devices
The spinal fusion segment accounted for the largest share of the global orthobiologics market in 2021. The segment is expected to be driven by the increase in number of spinal injuries and sports-related injuries during the forecast period. Demand for spinal fusion devices has been rising across the globe. Majority of spinal cord injuries are caused by avoidable incidences such as car accidents, falls, or violence. Traumatic spinal injury (TSI) occurs when bony, ligamentous, and/or neurologic structures of the spinal column are injured and result in significant morbidity and mortality.
Provision of Majority of Orthopedic Surgeries to Drive Hospitals Segment
In terms of end-user, the hospitals segment is projected to account for a major share of the global orthobiologics market during the forecast period. Orthopedic surgery is performed in hospitals on various parts such as the shoulder, ankle, hip, knee, wrists, elbow, and spine, depending on the type of injury or damage. Knee joint replacement, arthroscopy, pediatric orthopedic, and other minimally invasive orthopedic surgeries are the most commonly recommended procedures. Hence, the hospitals segment is likely to capture significant market share during the forecast period. Surgeries were traditionally performed in hospitals; however, advances in technology, anesthesia, and pain control now allow physicians to perform certain procedures in an orthopedic clinic center. This is projected to drive the orthopedic clinics segment in the next few years.
Regional Outlook of Global Orthobiologics Market
North America accounted for the largest share of around 45.9% of the global orthobiologics market in 2021. It is projected to be a highly lucrative region of the global market during the forecast period. Increase in demand for orthobiologics products, highly developed healthcare system, and availability of advanced therapy for orthopedic treatment are the factors driving the market in North America. The U.S. dominated the market in North America in 2021 due to the significant increase in spine injuries caused by falls and accidents in the country. According to the Department of Health and Human Services, two million people in the country suffer from sports-related injuries every year. There is also a greater understanding of orthobiologics and its benefits, such as accelerated healing capabilities, faster recoveries, and fewer hospital visits.
The market in Asia Pacific is expected to grow at a rapid pace during the forecast period. Rise in geriatric and target patient population, high incidence of osteoarthritis and obesity, increase in government healthcare spending, and improved healthcare infrastructure are the major factors driving the market in the region. Furthermore, Asia Pacific was the leading market for non-industry-sponsored osteoarthritis trials, accounting for a significant share in 2021.
Key Developments in Global Orthobiologics Market
Some of the prominent players in the Orthobiologics Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Orthobiologics market
By Geography
Key Benefits for Stakeholders
Chapter 1. Introduction
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Orthobiologics Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Orthobiologics Market Analysis and Forecast, 2017–2030
5. Key Insights
5.1. Key Market Trends
5.2. Merger and Acquisition
5.3. Strategies of Top Five Players Operating in the Market
5.4. Incidence of Orthopedic Disorder, by Key Countries
5.5. Regulatory and Reimbursement Scenario, by Key Countries
6. Global Orthobiologics Market Analysis and Forecast, by Product
6.1. Introduction & Definition
6.2. Market Value Forecast, by Product, 2017–2030
6.2.1. Demineralized Bone Matrix
6.2.2. Allografts
6.2.3. Synthetic Bone Substitutes
6.2.4. Viscosupplements
6.2.5. Bone Morphogenetic Proteins
6.2.6. Stem Cell Therapy
6.2.7. Others
6.3. Market Attractiveness, by Product
7. Global Orthobiologics Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Market Value Forecast, by Application, 2017–2030
7.2.1. Spinal Fusion
7.2.2. Trauma Repair
7.2.3. Reconstructive Surgeries
7.2.4. Others
7.3. Market Attractiveness Analysis, by Application
8. Global Orthobiologics Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Market Value Forecast, by End-user, 2017–2030
8.2.1. Hospitals
8.2.2. Orthopedic Clinics
8.2.3. Others
8.3. Market Attractiveness Analysis, by End-user
9. Global Orthobiologics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Orthobiologics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Product, 2017–2030
10.2.1. Demineralized Bone Matrix
10.2.2. Allografts
10.2.3. Synthetic Bone Substitutes
10.2.4. Viscosupplements
10.2.5. Bone Morphogenetic Proteins
10.2.6. Stem Cell Therapy
10.2.7. Others
10.3. Market Value Forecast, by Application, 2017–2030
10.3.1. Spinal Fusion
10.3.2. Trauma Repair
10.3.3. Reconstructive Surgeries
10.3.4. Others
10.4. Market Value Forecast, by End-user, 2017–2030
10.4.1. Hospitals
10.4.2. Orthopedic Clinics
10.4.3. Others
10.5. Market Value Forecast, by Country, 2017–2030
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Product
10.6.2. By Application
10.6.3. By End-user
10.6.4. By Country
11. Europe Orthobiologics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product, 2017–2030
11.2.1. Demineralized Bone Matrix
11.2.2. Allografts
11.2.3. Synthetic Bone Substitutes
11.2.4. Viscosupplements
11.2.5. Bone Morphogenetic Proteins
11.2.6. Stem Cell Therapy
11.2.7. Others
11.3. Market Value Forecast, by Application, 2017–2030
11.3.1. Spinal Fusion
11.3.2. Trauma Repair
11.3.3. Reconstructive Surgeries
11.3.4. Others
11.4. Market Value Forecast, by End-user, 2017–2030
11.4.1. Hospitals
11.4.2. Orthopedic Clinics
11.4.3. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017–2030
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Product
11.6.2. By Application
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Orthobiologics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product, 2017–2030
12.2.1. Demineralized Bone Matrix
12.2.2. Allografts
12.2.3. Synthetic Bone Substitutes
12.2.4. Viscosupplements
12.2.5. Bone Morphogenetic Proteins
12.2.6. Stem Cell Therapy
12.2.7. Others
12.3. Market Value Forecast, by Application, 2017–2030
12.3.1. Spinal Fusion
12.3.2. Trauma Repair
12.3.3. Reconstructive Surgeries
12.3.4. Others
12.4. Market Value Forecast, by End-user, 2017–2030
12.4.1. Hospitals
12.4.2. Orthopedic Clinics
12.4.3. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017–2030
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Product
12.6.2. By Application
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Orthobiologics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product, 2017–2030
13.2.1. Demineralized Bone Matrix
13.2.2. Allografts
13.2.3. Synthetic Bone Substitutes
13.2.4. Viscosupplements
13.2.5. Bone Morphogenetic Proteins
13.2.6. Stem Cell Therapy
13.2.7. Others
13.3. Market Value Forecast, by Application, 2017–2030
13.3.1. Spinal Fusion
13.3.2. Trauma Repair
13.3.3. Reconstructive Surgeries
13.3.4. Others
13.4. Market Value Forecast, by End-user, 2017–2030
13.4.1. Hospitals
13.4.2. Orthopedic Clinics
13.4.3. Others
13.5. Market Value Forecast, by Country/Sub-region, 2017–2030
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Product
13.6.2. By Application
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Orthobiologics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product, 2017–2030
14.2.1. Demineralized Bone Matrix
14.2.2. Allografts
14.2.3. Synthetic Bone Substitutes
14.2.4. Viscosupplements
14.2.5. Bone Morphogenetic Proteins
14.2.6. Stem Cell Therapy
14.2.7. Others
14.3. Market Value Forecast, by Application, 2017–2030
14.3.1. Spinal Fusion
14.3.2. Trauma Repair
14.3.3. Reconstructive Surgeries
14.3.4. Others
14.4. Market Value Forecast, by End-user, 2017–2030
14.4.1. Hospitals
14.4.2. Orthopedic Clinics;
14.4.3. Others
14.5. Market Value Forecast, by Country/Sub-region, 2017–2030
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Product
14.6.2. By Application
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company (2021)
15.3. Company Profiles
15.3.1. Medtronic
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. DePuy Synthes (Johnson & Johnson)
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Sanofi
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Seikagaku Corporation
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Stryker
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. MTF Biologics
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Bioventus LLC
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Arthrex
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Zimmer Biomet
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. RTI Surgical, Inc.
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
15.3.11. Alphatec Spine, Inc.
15.3.11.1. Company Overview
15.3.11.2. Product Portfolio
15.3.11.3. SWOT Analysis
15.3.11.4. Financial Overview
15.3.11.5. Strategic Overview
15.3.12. Exactech, Inc.
15.3.12.1. Company Overview
15.3.12.2. Product Portfolio
15.3.12.3. SWOT Analysis
15.3.12.4. Financial Overview
15.3.12.5. Strategic Overview
15.3.13. Globus Medical, Inc.
15.3.13.1. Company Overview
15.3.13.2. Product Portfolio
15.3.13.3. SWOT Analysis
15.3.13.4. Financial Overview
15.3.13.5. Strategic Overview
15.3.14. Integra LifeSciences
15.3.14.1. Company Overview
15.3.14.2. Product Portfolio
15.3.14.3. SWOT Analysis
15.3.14.4. Financial Overview
15.3.14.5. Strategic Overview
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers